Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Blinatumomab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ascentage's Olverembatinib Data in CML-LBP & Ph+ BCP-ALL at ASCO
    Ascentage's Olverembatinib Data in CML-LBP & Ph+ BCP-ALL at ASCO

    31 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/31/3303964/0/en/ascentage-pharma-presents-data-on-olverembatinib-in-cml-lbp-and-ph-bcp-all-at-asco-2026.html

    GLOBENEWSWIRE
    31 May 2026
    Share Share
    In8Bio Shows T Cell Engager Data For Autoimmune B Cell Depletion
    In8Bio Shows T Cell Engager Data For Autoimmune B Cell Depletion

    27 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/27/3174505/0/en/IN8bio-Presents-T-cell-Engager-Data-Demonstrating-Deep-B-Cell-Depletion-for-Autoimmune-Indications.html

    GLOBENEWSWIRE
    27 Oct 2025
    Share Share
    Cellectis Showcases Lasme-Cel's Potential For R/R B-ALL Patients
    Cellectis Showcases Lasme-Cel's Potential For R/R B-ALL Patients

    16 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/16/3168262/0/en/Cellectis-R-D-Day-Highlights-Lasme-cel-s-Potential-to-Address-Significant-Unmet-Need-for-Patients-with-r-r-B-ALL.html

    GLOBENEWSWIRE
    16 Oct 2025
    Share Share
    Amgen Finds Relief in Blincyto Patent Dispute with Lindis
    Amgen Finds Relief in Blincyto Patent Dispute with Lindis

    15 Aug 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/amgen-skirts-50m-payout-blincyto-patent-litigation-tiff-lindis

    FIERCE PHARMA
    15 Aug 2025
    Share Share
    Amgen`s Biologic Blincyto Receives Approval in US
    Amgen`s Biologic Blincyto Receives Approval in US

    29 Apr 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125557https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125557

    FDA
    29 Apr 2025
    Share Share
    EU Approves Blincyto® In CD19+ B-Cell ALL Consolidation Phase
    EU Approves Blincyto® In CD19+ B-Cell ALL Consolidation Phase

    29 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/european-commission-approves-blincyto-in-philadelphia-chromosome-negative-cd19-positive-b-cell-precursor-acute-lymphoblastic-leukemia-in-the-consolidation-phase-302363668.html

    PR NEWSWIRE
    29 Jan 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.